Diana Bilton

List of Publications by Citations

Source: https://exaly.com/author-pdf/3311981/diana-bilton-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74 papers	3,677 citations	29 h-index	60 g-index
89 ext. papers	4,537 ext. citations	6.1 avg, IF	5.17 L-index

#	Paper	IF	Citations
74	British Thoracic Society guideline for non-CF bronchiectasis. *Thorax*, **2010**, 65 Suppl 1, i1-58	7.3	625
73	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. *Science*, **2016**, 354, 751-757	33.3	314
72	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. *Thorax*, **2016**, 71 Suppl 1, i1-22	7.3	230
71	Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 975-82	10.2	187
70	Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. *BMJ: British Medical Journal*, **1998**, 316, 1771-5		156
69	Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. *Journal of Antimicrobial Chemotherapy*, **2005**, 55, 921-7	5.1	137
68	Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. *Journal of Cystic Fibrosis*, **2011**, 10 Suppl 2, S79-81	4.1	126
67	Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. *Chest*, **2006**, 130, 1503-10	5.3	121
66	Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema. *American Journal of Respiratory Cell and Molecular Biology*, **1998**, 18, 670-4	5.7	121
65	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. *Thorax*, **2016**, 71, 88-90	7.3	118
64	Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. *European Respiratory Journal*, **2011**, 38, 1071-80	13.6	117
63	Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. *Thorax*, **2014**, 69, 1073-9	7.3	108
62	Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. *Journal of Cystic Fibrosis*, **2013**, 12, 130-40	4.1	106
61	Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. *Journal of Cystic Fibrosis*, **2018**, 17, 218-227	4.1	90
60	Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. *BMJ, The*, **2011**, 342, d1008	5.9	84
59	Structural explanation for the deficiency of S alpha 1-antitrypsin. *Nature Structural Biology*, **1996**, 3, 910-1		76
58	Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. *Journal of Cystic Fibrosis*, **2020**, 19, 68-79	4.1	76

57	Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. *Chest*, **2013**, 144, 215-225	5.3	74
56	Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 744-51	5.9	69
55	Update on non-cystic fibrosis bronchiectasis. *Current Opinion in Pulmonary Medicine*, **2008**, 14, 595-9	3	55
54	Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. *Journal of Cystic Fibrosis*, **2013**, 12, 367-76	4.1	53
53	Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. *Respiratory Medicine*, **2014**, 108, 1397-408	4.6	47
52	BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. *Journal of Cystic Fibrosis*, **2014**, 13, 156-63	4.1	47
51	adaptation and diversification in the non-cystic fibrosis bronchiectasis lung. *European Respiratory Journal*, **2017**, 49,	13.6	46
50	Children and young adults with CF in the USA have better lung function compared with the UK. *Thorax*, **2015**, 70, 229-36	7.3	41
49	Data Resource Profile: The UK Cystic Fibrosis Registry. *International Journal of Epidemiology*, **2018**, 47, 9-10e	7.8	40
48	Placebo-Controlled Trials of Antioxidant Therapy Including S-Adenosylmethionine in Patients with Recurrent Nongallstone Pancreatitis. *Drug Investigation*, **1994**, 8, 10-20		34
47	Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis. *Clinical and Translational Science*, **2017**, 10, 28-34	4.9	33
46	HbA1c as a screening tool for cystic fibrosis related diabetes. *Journal of Cystic Fibrosis*, **2016**, 15, 251-7	4.1	30
45	The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study. *PLoS ONE*, **2019**, 14, e0212779	3.7	24
44	The reproducibility and responsiveness of the lung clearance index in bronchiectasis. *European Respiratory Journal*, **2015**, 46, 1645-53	13.6	23
43	Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations. *Journal of Cystic Fibrosis*, **2017**, 16, 36-40	4.1	20
42	Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. *Journal of Cystic Fibrosis*, **2020**, 19, 284-291	4.1	19
41	Global Lung Function Initiative equations improve interpretation of FEV1 decline among patients with cystic fibrosis. *European Respiratory Journal*, **2015**, 46, 262-4	13.6	18
40	Optimising inhaled mannitol for cystic fibrosis in an adult population. *Breathe*, **2015**, 11, 39-48	1.8	18

39	Relationship between pulmonary exacerbations and daily physical activity in adults with cystic fibrosis. *BMC Pulmonary Medicine*, **2015**, 15, 151	3.5	15
38	Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study. *Journal of Cystic Fibrosis*, **2015**, 14, 632-8	4.1	15
37	Eradication of respiratory tract MRSA at a large adult cystic fibrosis centre. *Respiratory Medicine*, **2015**, 109, 357-63	4.6	14
36	The diagnosis and management of respiratory tract fungal infection in cystic fibrosis: A UK survey of current practice. *Medical Mycology*, **2019**, 57, 155-160	3.9	14
35	Non-invasive ventilation and clinical outcomes in cystic fibrosis: Findings from the UK CF registry. *Journal of Cystic Fibrosis*, **2019**, 18, 665-670	4.1	13
34	The expanding armamentarium of drugs to aid sputum clearance: how should they be used to optimize care?. *Current Opinion in Pulmonary Medicine*, **2014**, 20, 601-6	3	11
33	Nurse specialist care for bronchiectasis. *The Cochrane Library*, **2003**,	5.2	11
32	The isolation and characterization of non-typeable Haemophilus influenzae from the sputum of adult cystic fibrosis patients. *European Respiratory Journal*, **1995**, 8, 948-53	13.6	11
31	Investigating the effects of long-term dornase alfa use on lung function using registry data. *Journal of Cystic Fibrosis*, **2019**, 18, 110-117	4.1	8
30	Effective strategies for managing new Pseudomonas cultures in adults with cystic fibrosis. *European Respiratory Journal*, **2015**, 46, 862-5	13.6	6
29	Laboratory Diagnosis and Characterization of Fungal Disease in Patients with Cystic Fibrosis (CF): A Survey of Current UK Practice in a Cohort of Clinical Microbiology Laboratories. *Mycopathologia*, **2018**, 183, 723-729	2.9	6
28	Randomised cross-over trial evaluating the short-term effects of non-invasive ventilation as an adjunct to airway clearance techniques in adults with cystic fibrosis. *BMJ Open Respiratory Research*, **2019**, 6, e000399	5.6	5
27	Results from an online survey of adults with cystic fibrosis: Accessing and using life expectancy information. *PLoS ONE*, **2019**, 14, e0213639	3.7	5
26	Knowledge of pancreatic enzyme supplementation in adult cystic fibrosis (CF) patients. *Journal of Human Nutrition and Dietetics*, **2000**, 13, 353-361	3.1	4
25	Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study. *Journal of Cystic Fibrosis*, **2021**,	4.1	4
24	Personalised medicine in cystic fibrosis must be made affordable. *Paediatric Respiratory Reviews*, **2014**, 15 Suppl 1, 6-7	4.8	3
23	Heterogeneity of treatment response in bronchiectasis clinical trials. *European Respiratory Journal*, **2021**,	13.6	3
22	The changing demography of the cystic fibrosis population: forecasting future numbers of adults in the UK. *Scientific Reports*, **2020**, 10, 10660	4.9	3

21	Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. *Journal of Cystic Fibrosis*, **2021**, 20, 1010-1017	4.1	3
20	Long-term safety study of colistimethate sodium (Colobreathe): Findings from the UK Cystic Fibrosis Registry. *Journal of Cystic Fibrosis*, **2021**, 20, 324-329	4.1	3
19	A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. *Journal of Cystic Fibrosis*, **2017**, 16, 695-701	4.1	2
18	A new chapter in therapy for cystic fibrosis. *Lancet Respiratory Medicine,the*, **2015**, 3, e20	35.1	2
17	Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-CF bronchiectasis patients		2
16	Response to Letter to the Editor: HbA1c as a screening tool for cystic fibrosis related diabetes: Response to letters by Widger et al. and Schnyder et al. *Journal of Cystic Fibrosis*, **2016**, 15, 265-6	4.1	1
15	S55 Towards the Clinical Application of Anti-pseudomonal Bacteriophage: Activity is Retained Following Nebulisation with a Range of Commercially Available Nebuliser Systems. *Thorax*, **2015**, 70, A34.1-A34	7.3	1
14	P236 Cystic Fibrosis deaths in USA and UK: comparisons of registry and routine data. *Thorax*, **2011**, 66, A163-A164	7.3	1
13	S48 Mucoidy and the microbiome: community composition in relation to the presence of culturable, mucoid Pseudomonas aeruginosa. *Thorax*, **2011**, 66, A24-A24	7.3	1
12	S103 Anti-Pseudomonal Bacteriophage Cocktail Reduces Inflammatory Responses in the Murine Lung. *Thorax*, **2012**, 67, A50.3-A51	7.3	1
11	Cholecystectomy as the treatment of choice in cystic fibrosis. *American Journal of Surgery*, **1990**, 160, 323-4	2.7	1
10	S66 The Gli Spirometry Reference Equations Influence The Apparent Rate Of Decline In Fev1 Among Children And Adolescents With Cystic Fibrosis. *Thorax*, **2014**, 69, A37-A37	7.3	
9	Azithromycin in bronchiectasis: evidence in children?. *Lancet Respiratory Medicine,the*, **2013**, 1, 587-589	35.1	
8	P220 Using funnel plots to make meaningful centre comparisons. *Thorax*, **2015**, 70, A187.2-A188	7.3	
7	USE OF APREPITANT AS AN ANTIEMETIC IN CYSTIC FIBROSIS PATIENTS. *BMJ Supportive and Palliative Care*, **2015**, 5, 118.2-119	2.2	
6	P175 The Short Term Variability of Sputum Microbiology in Non-CF Bronchiectasis. *Thorax*, **2012**, 67, A139.1-A139	7.3	
5	P100 Successful eradication of respiratory tract MRSA in cystic fibrosis: a retrospective study. *Thorax*, **2013**, 68, A120.1-A120	7.3	
4	P227 Disparities in care of adult CF patients in the UK. *Thorax*, **2010**, 65, A172-A173	7.3	

3	P103 Oral contraceptive use does not affect CF disease severity. *Thorax*, **2010**, 65, A121-A121	7.3
2	S122 Is There a Gender Difference in the UK CF Population?. *Thorax*, **2012**, 67, A59.1-A59	7.3
1	S123 The Role of Nasal Potential Difference Testing in Difficult Cases of Possible Cystic Fibrosis. *Thorax*, **2012**, 67, A59.2-A59	7.3